Quantum-Si (QSI) AI Stock Analysis

• Market Cap: $321.12M
• Dividend Yield: N/A
• Average Volume (3M): 9.86M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.64
• Revenue Growth: 167.94%
• EPS Growth: -3.66%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 46
• Industry: Biotechnology
• EPS (TTM): -0.11
• Shares Outstanding: 163,560,620
• 10 Day Avg. Volume: 6,724,356
• 30 Day Avg. Volume: 9,863,703
• PEG Ratio: 0.18
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.52
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 17.95
• Enterprise Value/Gross Profit: 103.45
• Enterprise Value/Ebitda: -0.49
• 1Y Price Target: $3.75
• Price Target Upside: 114.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 55 Neutral
• Price Target: $1.50 ▼(-14.29%Downside)

The overall score reflects strong revenue growth and international performance but is weighed down by ongoing profitability challenges and a negative valuation. Positive market momentum and strategic advancements offer potential upside, though risks in the U.S. market and financial strain persist.

Positive Factors

International Growth

The company reported that ex-US revenues made up nearly 85% of the total revenues for 1Q25, indicating strong international growth potential.

Partnerships

The recent partnership with Avantor is expected to provide support to grow sales in the biopharma sector.

Negative Factors

Market Penetration

It may take significant time before QSI can penetrate the protein sequencing opportunity.

Revenue Performance

The company reported total revenues of $808K, lower than consensus estimated revenue of $960K for 1Q25.

Quantum-Si Business Overview & Revenue Model

Company Description

Quantum-Si (QSI) is a biotechnology company focused on revolutionizing the field of proteomics through the development of next-generation protein sequencing technology. The company's core product is the Platinum™ platform, which aims to simplify and accelerate the analysis of proteins. By providing a more comprehensive understanding of proteins, Quantum-Si seeks to advance the discovery and development of new biomarkers and therapeutics, ultimately enhancing personalized medicine approaches.

How the Company Makes Money

Quantum-Si generates revenue primarily through the sale and deployment of its Platinum™ platform, which includes hardware, software, and consumables used for protein sequencing. The company also offers related services, such as data analysis and interpretation, which provide additional revenue streams. Quantum-Si's revenue model may include direct sales to research institutions, pharmaceutical companies, and clinical laboratories. Additionally, partnerships or collaborations with academic institutions and industry leaders may contribute to its earnings by expanding its market reach and driving adoption of its technology.

Quantum-Si Financial Statement Overview

Summary

Quantum-Si exhibits strong revenue growth but faces significant profitability challenges with negative margins and net losses. The balance sheet is robust with low leverage, yet cash flow remains a concern, reflecting ongoing operational challenges.

Income Statement

The company has shown strong revenue growth from $1.08 million in 2023 to $3.06 million in 2024, a significant improvement. However, gross profit margin is low at 52.33%, and the company is still operating at a substantial net loss of $101 million, resulting in a negative net profit margin of -3303.83%. EBIT and EBITDA margins are also deeply negative, indicating ongoing operational challenges.

Balance Sheet

Quantum-Si maintains a strong equity position with a debt-to-equity ratio of 0.06, indicating low financial leverage. The equity ratio is high at 86.89%, suggesting a strong balance sheet. However, the company still reports significant net losses, impacting return on equity, which is negative at -46.89%. This indicates inefficiencies in using equity to generate profit.

Cash Flow

Operating cash flow is negative at -$87.8 million, reflecting ongoing operational cash strains. There has been a slight improvement in free cash flow over the years, but it remains negative at -$92.4 million. The operating cash flow to net income ratio is 0.87, showing that cash flow is closely tracking net income losses, which is a concern.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
3.44M	3.06M	1.08M	0.00	0.00	0.00
	Gross Profit
1.82M	1.60M	488.00K	-2.58M	-1.04M	-894.00K
	EBIT
-110.33M	-108.58M	-111.17M	-123.84M	-96.91M	-36.69M
	EBITDA
-106.79M	-103.98M	-91.80M	-129.86M	-95.87M	-35.80M
	Net Income Common Stockholders
-100.72M	-101.01M	-95.96M	-141.04M	-88.95M	-36.61M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
232.60M	209.60M	257.74M	351.31M	471.30M	36.91M
	Total Assets
271.22M	247.87M	298.25M	391.49M	503.23M	40.59M
	Total Debt
12.05M	12.95M	15.30M	17.45M	8.08M	1.75M
	Net Debt
-25.24M	-36.29M	-118.56M	-66.87M	-27.71M	-35.16M
	Total Liabilities
24.30M	32.45M	26.63M	32.78M	26.19M	4.50M
	Stockholders Equity
246.92M	215.42M	271.62M	358.71M	477.03M	36.09M
Cash Flow		Free Cash Flow
-95.53M	-92.38M	-99.31M	-101.30M	-72.58M	-33.03M
	Operating Cash Flow
-90.74M	-87.80M	-94.04M	-90.56M	-66.81M	-32.57M
	Investing Cash Flow
-9.42M	-32.67M	143.43M	137.19M	-450.94M	-461.00K
	Financing Cash Flow
84.31M	35.88M	149.00K	1.91M	516.63M	37.01M

Quantum-Si Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.75
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For QSI, the sentiment is Positive. The current price of 1.75 is above the 20-day moving average (MA) of 1.73, above the 50-day MA of 1.45, and above the 200-day MA of 1.44, indicating a bullish trend. The MACD of 0.07 indicates Positive momentum. The RSI at 55.16 is Neutral, neither overbought nor oversold. The STOCH value of 46.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for QSI.

Quantum-Si Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CMPX	60 Neutral	$329.11M	―	-41.31%	―	―	-7.93%
QSI	55 Neutral	$321.12M	―	-40.23%	―	167.94%	-3.66%
SEER	54 Neutral	$116.52M	―	-24.73%	―	-1.02%	-8.59%
Sector *	54 Neutral	$5.24B	3.26	-44.35%	6.48%	16.78%	-0.10%
FHTX	49 Neutral	$264.77M	―	322.49%	―	-30.66%	36.48%
AVIR	47 Neutral	$274.71M	―	-30.47%	―	―	-22.66%
NAUT	41 Neutral	$89.31M	―	-30.93%	―	―	-1.20%

Quantum-Si Corporate Events

Quantum-Si Shareholders Approve Key Proposals at Annual Meeting

On May 16, 2025, Quantum-Si held its Annual Meeting where shareholders voted on three key proposals. The meeting saw the reelection of board members, the ratification of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year ending December 31, 2025, and the approval of executive compensation, reflecting strong shareholder support for the company’s governance and financial strategies.

The most recent analyst rating on (QSI) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Quantum-Si stock, see the QSI Stock Forecast page.

Quantum-Si Updates Corporate Strategy in Proteomics

On April 10, 2025, Quantum-Si Incorporated updated its corporate presentation, highlighting its strategic positioning in the expanding proteomics market. The company’s Proteus platform, expected to launch in the second half of 2026, aims to revolutionize proteomics research by offering single-molecule, top-down, and bottom-up methods. Quantum-Si’s technology is designed to address the complexities of proteomics analysis and is anticipated to transform the field from a complementary to a primary technology in research. The company’s advancements are expected to accelerate commercial adoption, evidenced by a 183% year-over-year growth.